Refine by
Immunotherapy Suppliers & Manufacturers
168 companies found
based inSan Francisco, CALIFORNIA (USA)
Xcell Bio is a San Francisco-based life science company dedicated to bringing an innovative primary cell control solution to the immunotherapy market to support research, drug discovery, and cell manufacturing. Xcell’s mission is to democratize ...
based inGlasgow, UNITED KINGDOM
We’re a leading microbiome therapeutics company. We have established proprietary MHRA licensed manufacturing capabilities and a supply chain model that enables us to leverage a pipeline of internal and partnered programmes around our lead asset, ...
Immuno-oncology exploits the mechanisms of the body’s own natural immune response, either by stimulating or suppressing it, to fight ...
based inStockholm, SWEDEN
BioArctic is a Swedish research intensive biopharma company aimed at developing new treatments that address the causes of disorders that affect the Central Nervous System. These types of treatments are commonly referred to as disease modifiers. They ...
In Alzheimer’s disease soluble, toxic amyloid beta aggregates are believed to contribute to the neurodegenerative process. Lecanemab, a anti amyloid-beta protofibril antibody, selectively binds to these forms of amyloid beta and eliminates ...
based inPhiladelphia, PENNSYLVANIA (USA)
Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity ...
based inSanta Barbara, CALIFORNIA (USA)
Owl Biomedical, Inc. was founded in 2011 to expand the use of its exclusive cell sorting MEMS technology for cell therapy, cancer diagnostics and basic research. Operating in Santa Barbara, California, Owl Biomedical was purchased in 2013 by ...
based inSan Francisco, CALIFORNIA (USA)
Cypre is a biotechnology company dedicated to overcoming therapeutic resistance for cancer patients. Our 3D Tumor Model Platform engineers the tumor microenvironment in vitro at high throughput for drug efficacy and MOA studies. We are now applying ...
Cypre’s 3D Tumor Models combine the tumor, stromal and immune compartments in a high throughput format to screen targeted drugs and immunotherapy. In 2021, we partnered with Charles River to offer our 3D Tumor Models for drug ...
based inGlasgow, UNITED KINGDOM
Our mission is to enhance decision making within R&D by leveraging Digital Pathology to deliver robust data and actionable insights. OracleBio is a global leader in quantitative digital pathology, providing image analysis services to Pharma and ...
Quantitative Digital Pathology provides deep insights into the tumor microenvironment (TME), a knowledge which is crucial for understanding the mechanism of action of new oncology immunotherapies or for investigating new biomarkers. ...
based inSchlieren, SWITZERLAND
Elthera AG is a Swiss biopharmaceutical company founded in 2016 by experienced Pharma and Biotech executives with the goal of developing proprietary, first-in-class oncology drugs using a personalized health care approach. Elthera AG is developing ...
L1 cell adhesion molecule (L1CAM) is a cell surface protein which is aberrantly expressed in many different tumor types including pancreatic, ovarian, breast, lung, and colorectal cancer. L1CAM expression increases the malignancy of these ...
based inLondon, UNITED KINGDOM
Treos Bio is a clinical stage company introducing a disruptive computational technology to change the paradigm of cancer immunotherapy development by resolving the dual challenges of patient and tumor heterogeneity. We use proprietary therapeutic ...
Using our proprietary computational vaccine design technology, we have developed a PolyPEPI preventive peptide vaccine against COVID-19 (SARS-CoV-2). The design of PolyPEPI-SCoV-2 exploits our knowledge on genetic heterogeneity of individuals ...
based inMadison, WISCONSIN (USA)
Through a lot of hard work, a license from the Wisconsin Alumni Research Foundation (WARF) and a desire to have an impact on human health, NeoClone was founded in 1999 by three University of Wisconsin scientists who recognized the need for better ...
NeoClone is fast becoming a leader in the single domain antibody library field. We offer a wide range of unique services, including construction of immunized single domain antibody libraries using our llamas, bio-panning of naïve or immunized ...
based inSyracuse, NEW YORK (USA)
Mesothelioma is an aggressive cancer that affects the lining of the lungs, heart, or abdomen. Caused by the inhalation of asbestos fibers, mesothelioma is often diagnosed in older individuals who worked with asbestos products. Prognosis for ...
There is no cure for mesothelioma, but clinical trials and experimental treatments offer hope for the future. In the never-ending effort to eradicate cancer, there are medical and scientific researchers constantly looking for new ways to attack this ...
based inDallas, TEXAS (USA)
Lupagen is a privately held early stage biotech company developing first-in-class bedside enabled cell & gene therapies (CAR-T cell, gene editing and immunotherapy products) based on their patent-pending bedside point-of-care C and GT production and ...
based inEttlingen, GERMANY
We are a pioneering medical device company focused on transforming the lives of patients with difficult to treat cancers by applying our discoveries in bioelectromagnetics to targeted treatment of cancer. Our patient-based research using low and ...
The TheraBionic P1 produces low levels radiofrequency (RF) electromagnetic fields, which are amplitude-modulated at tumor-specific frequencies. The device is coupled with a spoon-shaped antenna, which is placed in the patient’s mouth, more ...
based inMorrisville, NORTH CAROLINA (USA)
Istari Oncology, Inc., is a clinical-stage biotechnology company developing innovative immunotherapies for the treatment of patients with solid tumors. Istari has built a passionate and experienced leadership team focused on clinical trial strategy ...
The tumor environment contains all the ingredients needed to mount an anticancer immune response—tumor antigens, antigen presenting cells (APCs, including tumor-associated macrophages [TAMs] and dendritic cells), and T cells—but ...
based inVilligen, SWITZERLAND
leadXpro specializes in structure-based drug discovery for membrane proteins. leadXpro is a team of experts in membrane protein science. We have an integrated platform for membrane protein biochemistry, biophysics and structural biology, including ...
Using X-ray structure-based molecular design, leadXpro has discovered, optimised and patented two new series of selective antagonists of the A2B adenosine receptor. ...
based inLos Angeles, CALIFORNIA (USA)
MiraDx partners with universities and pharmaceutical companies to utilize our unique genetic research to help better treat cancer. MiraDx was co-founded by Joanne Weidhaas, M.D., Ph.D. and Frank Slack, Ph.D. whose cutting-edge genetic research ...
We are working with potential partners to incorporate these findings into the newer agents to allow better patients selection to achieve improved response and less toxicity from these exciting new therapies. We are additionally working with partners ...
based inSherbrooke, QUEBEC (CANADA)
At Immune Biosolutions (IBio), we strongly believe that biologics can transform and save lives. Leveraging our technology platforms, we hack the immune system of chickens to discover and engineer the next generation of immunotherapies. We create ...
Leveraging our technology platforms, we hack the immune system of chickens to discover and engineer the next generation of immunotherapies. ...
based inTuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
ACTallo® is a process developed by Immatics for the manufacture of allogeneic, off-the-shelf, TCR-engineered cellular therapies derived from healthy donors’ gamma delta T ...
based inGaithersburg, MARYLAND (USA)
NexImmune is a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIMâ„¢) technology. AIM nanoparticles act as synthetic dendritic cells to deliver ...
NexImmune’s AIM™ platform is the foundation for our unique approach to immunotherapy. Our AIM nanoparticle technology enables the development of immunotherapies that orchestrate specific T cell function ...
based inAbingdon, UNITED KINGDOM
PsiOxus is a clinical-stage company redefining therapies for solid tumors with the goal of curing patients with cancer. Our clinically validated, systemically dosed T-SIGn® viral vector platform delivers tumor-localized production of combinations of ...
Our clinically validated T-SIGn® viral vector platform delivers multiple transgene payloads that re-program the tumor microenvironment of both primary and metastatic tumors. Our platform can integrate rationally designed synthetic agents to ...